CA
CNCR

Calton & Associates’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Calton & Associates’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-50
Closed -$1K – 501
2017
Q4 		$1K Buy
+50
New +$1.26K ﹤0.01% 1431

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Calton & Associates's CNCR Position: Q1 2018 in Review

Calton & Associates sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q1 2018, closing a stake of 50 shares — an estimated $1K sold.

Calton & Associates first reported a position in CNCR in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 23 funds tracked by Wall St. Rank hold CNCR as of Q1 2018.

  • Calton & Associates reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q1 2018 after selling out during the quarter.
  • Calton & Associates sold 50 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q1 2018, an estimated $1K.
  • Calton & Associates first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2017 and held it in 1 quarter.
  • Calton & Associates's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $1K in Q4 2017.
  • 23 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.